New stroke drug shows no benefit for patients treated with clot-busting therapy

Stroke survivors often face a long road to recovery. Many hope for new medicines that help them walk again or speak clearly. A large study tested a drug called glenzocimab to see if it could help people who had an acute ischemic stroke. This is a sudden blockage of blood flow to the brain. Doctors treated these patients with thrombolysis, a procedure that dissolves clots, within 4.5 hours of symptoms starting. Some also received mechanical thrombectomy to physically remove the blockage. The trial included 438 patients across 54 centers in 10 countries. Researchers gave some patients 1000 mg of glenzocimab through an IV. Others received a placebo, which looks like the real drug but has no active medicine. The main goal was to see if fewer people ended up with severe disability after 90 days. Severe disability means needing help with daily tasks like bathing or eating. The results showed no difference between the two groups. About 21.6 percent of those on the drug had severe disability. That was higher than the 15.3 percent in the placebo group. The difference was not statistically significant. This means the drug did not work as hoped for this specific group of patients. Safety checks showed similar rates of bleeding in the brain for both groups. No major safety signals emerged. The study confirms that glenzocimab does not help stroke patients who already received standard clot-busting therapy. This is important news for doctors and families looking for new options. It shows that not every new drug will work for every patient.